All In Biotech

Free tool

FAERS Monitor: Glyxambi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 206073 or its brand name (Glyxambi, Empagliflozin, Linagliptin). Reports on generic versions are filed under their own applications.

Reports

1,966

Serious

894

45% of reports

Hospitalization

479

Death reported

65

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • blood glucose increased152
  • diabetic ketoacidosis149
  • nausea106
  • fungal infection92
  • weight decreased87
  • dizziness76
  • vomiting71
  • urinary tract infection66
  • fatigue59
  • drug ineffective56
  • diarrhoea50
  • headache49
  • dehydration48
  • off label use43
  • euglycaemic diabetic ketoacidosis41

Reports by year received

View as table
YearReports
2015209
2016298
2017172
2018182
2019211
2020192
2021165
2022122
2023142
2024105
202596
202672

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,193 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
euglycaemic diabetic ketoacidosisSignal41107.379.14,171
diabetic ketoacidosisSignal14966.857.29,539
fungal infectionSignal9229.624.22,512
blood glucose increasedSignal1528.67.41,027
urinary tract infectionSignal664.13.3155
dehydrationSignal483.92.999
weight decreasedSignal873.32.7142
dizziness761.61.318
vomiting711.61.316
nausea1061.41.214
headache490.80.61
diarrhoea500.80.62
fatigue590.80.63
off label use430.50.419
drug ineffective560.50.439

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.